{"id":849646,"date":"2025-05-09T16:33:10","date_gmt":"2025-05-09T20:33:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/"},"modified":"2025-05-09T16:33:10","modified_gmt":"2025-05-09T20:33:10","slug":"rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/","title":{"rendered":"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy"},"content":{"rendered":"

<\/p>\n

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th<\/sup> Annual Meeting of the American Society of Gene and Cell Therapy<\/b><\/p>\n

CRANBURY, N.J.–(BUSINESS WIRE<\/a>)–Rocket Pharmaceuticals, Inc.<\/a> (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held from May 13-17 in New Orleans, LA.\n<\/p>\n

\nDetails for the oral presentation of the abstract at ASGCT are as follows:\n<\/p>\n

Title<\/b>: Preliminary Data from a Phase I Gene Therapy Trial of RP-A601 (AAVrh.74-PKP2a) for Adult Patients with PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM)
\n
Session: <\/b>Late-Breaking Abstracts I
\n
Presenter<\/b>: Barry H. Greenberg, MD, FHFSA, Distinguished Professor of Medicine at University of California San Diego School of Medicine and Director of the Advanced Heart Failure Treatment Program at UC San Diego Health
\n
Date and Time<\/b>: Thursday, May 15, from 2:00-2:15 p.m. CT\n<\/p>\n

\nRocket plans to host an investor webinar on May 15, 2025, at 4:30 p.m. ET. To join the investor webinar, please register at https:\/\/www.webcaster4.com\/Webcast\/Page\/3046\/52359<\/a>. Webinar details will be posted on the Events and Presentations<\/a> page of the Rocket website at www.RocketPharma.com<\/a>.\n<\/p>\n

About RP-A601<\/b><\/p>\n

\nRP-A601 is an investigational gene therapy for the treatment of plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM). RP-A601 consists of a recombinant adeno-associated serotype rh74 capsid containing a functional version of the human PKP2<\/i> transgene (AAVrh74.PKP2) which is administered as a single intravenous (IV) infusion. RP-A601 is being investigated as a one-time, potentially curative gene therapy treatment that may improve survival and quality of life for patients affected by PKP2-ACM. Rocket holds Fast Track designation in the U.S. and Orphan Drug designation in the U.S. and Europe for the program.\n<\/p>\n

About PKP2-Arrhythmogenic Cardiomyopathy (PKP2-ACM)<\/b><\/p>\n

\nPKP2-ACM is an inherited heart disease caused by mutations in the PKP2<\/i> gene and characterized by life-threatening ventricular arrhythmias, cardiac structural abnormalities, and sudden cardiac death. PKP2-ACM affects approximately 50,000 adults and children in the U.S. and Europe. Patients living with PKP2-ACM have an urgent unmet medical need, as current medical, implantable cardioverter defibrillator (ICD), and ablation therapies do not consistently prevent disease progression or arrhythmia recurrence, are associated with significant morbidity including inappropriate shocks and device and procedure-related complications, and do not address the underlying pathophysiology or genetic mutation.\n<\/p>\n

About Rocket Pharmaceuticals, Inc.<\/b><\/p>\n

\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket\u2019s innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives.\n<\/p>\n

\nRocket\u2019s adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, an early-stage program in clinical trials for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death, and a pre-clinical program targeting BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles.\n<\/p>\n

\nRocket\u2019s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia.\n<\/p>\n

\nFor more information about Rocket, please visit www.rocketpharma.com<\/a> and follow us on LinkedIn<\/a>, YouTube,<\/a> and X<\/a>.\n<\/p>\n

Rocket Cautionary Statement Regarding Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements concerning Rocket\u2019s future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as \u201ccould,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cwill give,\u201d \u201cestimate,\u201d \u201cseek,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201csuggest\u201d or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket\u2019s expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket\u2019s ongoing and planned clinical trials, the expected timing and outcome of Rocket\u2019s regulatory interactions and planned submissions, including the timing and outcome of the FDA\u2019s review of the additional CMC information that Rocket will provide in response to the FDA\u2019s request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket\u2019s ability to establish key collaborations and vendor relationships for its product candidates, Rocket\u2019s ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket\u2019s ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket’s ability to transition to a commercial stage pharmaceutical company, and Rocket\u2019s expectation that its cash, cash equivalents and investments will be sufficient to funds its operations into the third quarter of 2026. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket\u2019s dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket\u2019s competitors\u2019 activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket\u2019s ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket\u2019s ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket\u2019s ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in Rocket\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, filed February 27, 2025 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250509219128\/en\/<\/a><\/span><\/p>\n

Investors
\n<\/b>
Meg Dodge
\n
mdodge@rocketpharma.com<\/a><\/p>\n

Media
\n<\/b>
Kevin Giordano
\n
media@rocketpharma.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America Louisiana New Jersey<\/p>\n

INDUSTRY KEYWORDS:<\/b> Cardiology Biotechnology FDA Professional Services Other Health Health General Health Pharmaceutical Genetics Clinical Trials Finance<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held from May 13-17 in New Orleans, LA. Details for the oral presentation of the … <\/p>\n

Continue reading “Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-849646","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held from May 13-17 in New Orleans, LA. Details for the oral presentation of the … Continue reading "Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-09T20:33:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy\",\"datePublished\":\"2025-05-09T20:33:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/\"},\"wordCount\":1341,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/\",\"name\":\"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-05-09T20:33:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/","og_locale":"en_US","og_type":"article","og_title":"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Market Newsdesk","og_description":"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the company will be presenting data for the first time from the Phase 1 clinical trial of RP-A601 to treat patients with plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM) at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held from May 13-17 in New Orleans, LA. Details for the oral presentation of the … Continue reading \"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-09T20:33:10+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy","datePublished":"2025-05-09T20:33:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/"},"wordCount":1341,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/","name":"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-05-09T20:33:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250509219128r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rocket-pharmaceuticals-announces-late-breaking-oral-presentation-of-data-from-phase-1-clinical-trial-of-rp-a601-for-pkp2-arrhythmogenic-cardiomyopathy-accepted-at-28th-annual-meeting-of-the-american-s\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849646","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=849646"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/849646\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=849646"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=849646"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=849646"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}